Chundong Gu

Dr. Chundong Gu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QXQiang Xie
Qiang Xie
FLFengzhou Li
Fengzhou Li
LFLei Fang
Lei Fang
WLWenzhi Liu
Wenzhi Liu
CGChundong Gu
Chundong Gu
Inflammatory mediators and inflammatory cells in the inflammatory microenvironment promote the transformation of normal cells to cancer cells in the early stage of cancer, promote the growth and development of cancer cells, and induce tumor immune escape. The monomeric active ingredient β‐elemene is extracted from the traditional Chinese medicine Curcuma wenyujin and has been proven to have good anti‐inflammatory and antitumor activities in clinical applications for more than 20 years in China. Recent studies have found that this traditional Chinese medicine plays a vital role in macrophage infiltration and M2 polarization, as well as in regulating immune disorders, and it even regulates the transcription factors NF‐κB and STAT3 to alter inflammation, tumorigenesis, and development. In addition, β‐elemene regulates not only different inflammatory factors (such as TNF‐α, IFN, TGF‐β, and IL‐6/10) but also oxidative stress in vivo and in vitro. The excellent anti‐inflammatory and antitumor effects of β‐elemene and its ability to alter the inflammatory microenvironment of tumors have been gradually elaborated. Although the study of monomeric active ingredients in traditional Chinese medicines is insufficient in terms of quality and quantity, the pharmacological effects of more active ingredients of traditional Chinese medicines will be revealed after β‐elemene.

19 June 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YCYanwei Cui
Yanwei Cui
FLFengzhou Li
Fengzhou Li
QXQiang Xie
Qiang Xie
SZShilei Zhao
Shilei Zhao
TGTao Guo
Tao Guo
CGChundong Gu
Chundong Gu
Y-box binding protein 1 (YBX1) is involved in the development of multiple types of tumors. However, the relationship between YBX1 and autophagy in non-small cell lung cancer (NSCLC) remains unclear. In this study, we analyzed the expression and clinical significance of YBX1 and markers of autophagy (LC3I/II) in NSCLC and examined their roles in regulating sensitivity to cisplatin in NSCLC. The retrospective analysis of patients with NSCLC indicated that YBX1 was positively correlated with autophagy. Increased levels of YBX1 or autophagy also observed in NSCLC cells compared with those in 16HBE cells. Compared to the controls, the knockdown of YBX1 expression suppressed autophagy, increased drug sensitivity and promoted apoptosis in response to cisplatin in NSCLC cells by targeting the p110β promoter and inhibiting p110β/Vps34/beclin1 signaling pathways. We also demonstrated in an in vivo study that the overexpressed YBX1 effectively increased NSCLC growth and progression and decreased the sensitivity to cisplatin by inducing autophagy in a xenograft tumor model, and these effects were concomitant with the increasing of p110β and beclin1 expression. Collectively, these results show that YBX1 plays an essential role in autophagy in NSCLC.

15 December 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
QXQiang Xie
Qiang Xie
SZShilei Zhao
Shilei Zhao
WLWenzhi Liu
Wenzhi Liu
YCYanwei Cui
Yanwei Cui
FLFengzhou Li
Fengzhou Li
CGChundong Gu
Chundong Gu
Abnormal expression of the transcription factor Y-box-binding protein-1 (YBX1) is associated with the proliferation, migration, aggressiveness, and stem-like properties of various cancers. These characteristics contribute to the tumorigenesis and metastasis of cancer. We found that the expression levels of Mucin-1 (MUC1) and YBX1 were positively correlated in lung adenocarcinoma cells and lung adenocarcinoma tissue. Our retrospective cohort study of 176 lung adenocarcinoma patients after surgery showed that low expression of both YBX1 and MUC1 was an independent predictor of the prognosis and recurrence of lung adenocarcinoma. In lung adenocarcinoma cells, the silencing/overexpression of YBX1 caused a simultaneous change in MUC1, and MUC1 overexpression partially reversed the decreased tumor cell migration, aggressiveness, and stemness caused by YBX1 silencing. Moreover, chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays proved that MUC1 was the downstream target of YBX1 and that YBX1 bound to the -1480~-1476 position in the promoter region of MUC1 to regulate its transcription. Furthermore, in mouse xenograft models and a lung cancer metastasis model, MUC1, which is downstream of YBX1, partially reversed the decreased number and size of tumors caused by YBX1 silencing. In conclusion, our findings indicated a novel mechanism by which YBX1 promotes the stemness and metastasis of lung adenocarcinoma by targeting MUC1 and provided a combination approach for diagnosis different from traditional single tumor biomarkers to predict patient prognosis and provide clinical treatment targets.

1 January 2020
Verified
Journal Article
Closed access
FLFengzhou Li
Fengzhou Li
SZShilei Zhao
Shilei Zhao
YCYanwei Cui
Yanwei Cui
TGTao Guo
Tao Guo
JQJiaqi Qiang
Jiaqi Qiang
TWTaihua Wu
Taihua Wu

1 May 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
TGTao Guo
Tao Guo
JKJing Kong
Jing Kong
YLYang Liu
Yang Liu
ZLZhuoshi Li
Zhuoshi Li
JXJianglong Xia
Jianglong Xia
CGChundong Gu
Chundong Gu
Aberrant overexpression of the transcription/translation factor Y-box-binding protein-1 (YBX1) is associated with non-small cell lung cancer (NSCLC) aggressiveness. Cancer stem cells (CSCs) contribute to the tumorigenesis and metastasis of NSCLC. Hitherto, the mechanism by which YBX1 regulates CSCs and metastasis in NSCLC remains unclear. Here, we demonstrated that YBX1 levels were elevated in NSCLC tissues and cell lines. Enforced expression of YBX1 promoted NSCLC cells invasion, sphere forming ability and ALDH1+ population. Conversely, reduced YBX1 impaired CSC properties of NSCLC cells in vitro and tumor-initiating frequencies, as well as metastasis in vivo. Importantly, we described a mechanism whereby YBX1 directly promoted NANOG, a transcription factor, transcriptional activation. Depletion of NANOG abolished the enhanced ability of invasion and sphere formation in YBX1 elevated-A549 cells. Collectively, these findings demonstrate a novel role of YBX1 in maintaining the stemness of CSCs and metastasis, unveiling YBX1 as promising therapeutic target for NSCLC treatments.

29 May 2017 in Oncotarget
Verified
Journal Article
Open access
TGTao Guo
Tao Guo
SZShilei Zhao
Shilei Zhao
PWPeng Wang
Peng Wang
XXXiaoyuan Xue
Xiaoyuan Xue
YZYan Zhang
Yan Zhang
CGChundong Gu
Chundong Gu
YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma